(Q47664404)

English

A single vaccination with protein-microspheres elicits a strong CD8 T-cell-mediated immune response against Mycobacterium tuberculosis antigen Mtb8.4.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/15121309

A single vaccination with protein-microspheres elicits a strong CD8 T-cell-mediated immune response against Mycobacterium tuberculosis antigen Mtb8.4. (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/15121309

Mycobacterium tuberculosis

0 references

1 reference

based on heuristic

inferred from title

author name string

Jay T Evans

1

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/15121309

Jon R Ward

2

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/15121309

Jeff Kern

3

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/15121309

Mark E Johnson

4

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/15121309

language of work or name

0 references

publication date

1 May 2004

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/15121309

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/15121309

22

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/15121309

15-16

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/15121309

1964-1972

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/15121309

Determination of the prevalence of infection with Mycobacterium tuberculosis among persons vaccinated against Bacillus Calmette-Guérin in South Korea

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.035

7 January 2021

Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.035

7 January 2021

A novel TB vaccine; towards a strategy based on our understanding of BCG failure.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.035

7 January 2021

Vaccination with the T cell antigen Mtb 8.4 protects against challenge with Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.035

7 January 2021

Immunology of tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.035

7 January 2021

CD8(+) T cells participate in the memory immune response to Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.035

7 January 2021

Control of latent Mycobacterium tuberculosis infection is dependent on CD8 T cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.035

7 January 2021

Major histocompatibility complex class I-restricted T cells are required for resistance to Mycobacterium tuberculosis infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.035

7 January 2021

Genetic adjuvants for DNA vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.035

7 January 2021

Pulmonary necrosis resulting from DNA vaccination against tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.035

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.035

7 January 2021

Phase II study of alpha-interferon and 13-cis-retinoic acid in metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.035

7 January 2021

Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.035

7 January 2021

Effect of the size and surface charge of polymer microspheres on their phagocytosis by macrophage

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.035

7 January 2021

Fully mobilizing host defense: building better vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.035

7 January 2021

Targeting antigen into the phagocytic pathway in vivo induces protective tumour immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.035

7 January 2021

A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.035

7 January 2021

Controlled delivery systems for proteins based on poly(lactic/glycolic acid) microspheres

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.035

7 January 2021

Therapeutic effects of leuprorelin microspheres on endometriosis and uterine leiomyomata

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.035

7 January 2021

Design of biodegradable particles for protein delivery

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.035

7 January 2021

Towards clinical testing of a single-administration tetanus vaccine based on PLA/PLGA microspheres

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.035

7 January 2021

Biodegradable microspheres containing influenza A vaccine: immune response in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.035

7 January 2021

A novel microencapsulated peptide vaccine against hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.035

7 January 2021

Immunization with a soluble recombinant HIV protein entrapped in biodegradable microparticles induces HIV-specific CD8+ cytotoxic T lymphocytes and CD4+ Th1 cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.035

7 January 2021

Biodegradable microspheres as a vaccine delivery system

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.035

7 January 2021

Microspheres containing plasmid-encoded antigens elicit cytotoxic T-cell responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.035

7 January 2021

Biodegradable microparticles as a delivery system for measles virus cytotoxic T cell epitopes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.035

7 January 2021

Induction of a cytotoxic T lymphocyte response by immunization with a malaria specific CTL peptide entrapped in biodegradable polymer microspheres

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.035

7 January 2021

A single administration of tetanus toxoid in biodegradable microspheres elicits T cell and antibody responses similar or superior to those obtained with aluminum hydroxide

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.035

7 January 2021

Hydrophobic ion pairing: altering the solubility properties of biomolecules

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.035

7 January 2021

Monophosphoryl lipid A activates both human dendritic cells and T cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.035

7 January 2021

Monophosphoryl lipid A enhances mucosal and systemic immunity to vaccine antigens following intranasal administration

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.035

7 January 2021

Synthesis and biological evaluation of a new class of vaccine adjuvants: aminoalkyl glucosaminide 4-phosphates (AGPs)

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.035

7 January 2021

Novel anionic microparticles are a potent adjuvant for the induction of cytotoxic T lymphocytes against recombinant p55 gag from HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.035

7 January 2021

Enhancement of the human T cell response to culture filtrate fractions of Mycobacterium tuberculosis by microspheres

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.035

7 January 2021

Factors affecting the degradation rate of poly(lactide-co-glycolide) microspheres in vivo and in vitro

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.035

7 January 2021

Immunogenicity and protection in small-animal models with controlled-release tetanus toxoid microparticles as a single-dose vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.035

7 January 2021

based on heuristic

inferred from DOI database lookup

Biodegradable and biocompatible poly(DL-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.035

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2003.10.035

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/15121309

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/15121309

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47664404&oldid=1382062863"